IB1001 TRIAL

March 1, 2023

IB1001 TRIAL Ongoing Studies and Trials for A-T

Investigator:

IntraBio, Inc.

Purpose:

This open label, rater blinded study is being performed to determine the efficacy of N-Acetyl-L-Leucine (IB1001) to treat certain neurological symptoms associated with A-T. Detailed information about this trial can be found at clinicaltrials.gov. (ClinicalTrials.gov Identifier: NCT03759678).

Location:

United States (California), United Kingdom